{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:54Z","timestamp":1787027034192,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The current standard of care for newly diagnosed glioblastoma (GBM) is maximum surgical resection followed by concurrent treatment with temozolomide (TMZ) and radiotherapy (RT) and then six to twelve cycles of maintenance TMZ. RRx-001, an NLRP3 inhibitor and nitric oxide (NO) donor with chemoradiosensitizing, vascular normalizing and macrophage repolarizing properties, is currently in a Phase III trial for small cell lung cancer (SCLC). The purpose of this non-randomized trial was to establish the safety and look for a signal of clinical activity of RRx-001 as an add-on to RT and TMZ in patients with newly diagnosed glioblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this non-randomized, open-label, two part trial called G-FORCE-1 (NCT02871843), the first four cohorts of adult patients with histologically confirmed high grade gliomas received fractionated radiotherapy (60 Gy in 30 fractions over 6 weeks), daily 75 mg\/m2 temozolomide and escalating doses of once weekly RRx-001 from 0.5 mg to 4 mg according to a 3+3 design followed by a 6 week no treatment interval and then standard maintenance TMZ (150 mg\/m2 Cycle 1 and 200 mg\/m2 in subsequent cycles) until disease progression. The second two cohorts of patients received fractionated radiotherapy (60 Gy in 30 fractions over 6 weeks), daily 75 mg\/m2 temozolomide and once weekly RRx-001 4 mg followed by a 6 week no treatment interval and then two different maintenance schedules until disease progression according to the same 3+ 3 design: 1. 0.5 mg RRx-001 once weekly + 100 mg\/m2 TMZ 5 days\/week for up to 6 cycles of therapy; 2. 4 mg RRx-001 once weekly + 100 mg\/m2 TMZ 5 days\/week for up to 6 cycles of therapy<\/jats:p>\n                    <jats:p>The primary endpoint was the recommended dose\/maximally tolerated dose of the combination of RRx-001, TMZ and RT. Secondary endpoints were overall survival, progression free survival, objective response rate, duration of response and clinical benefit response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 newly diagnosed glioblastoma patients were enrolled. No dose limiting toxicities were observed and no MTD was reached. The recommended dose is 4 mg. After 24 months of follow up the median OS was 21.9 months (95% CI: 11.7 \u2013 NA). PFS median was 8 months (95% CI: 5 \u2013 NA). The overall response rate was 18.8% (3 PR out of 16) and the disease control rate was 68.8% (3 PR, 8 SD out of 16).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of RRx-001 to TMZ and RT and to TMZ during maintenance was safe and well-tolerated and deserves further study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2023.1176448","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:58:50Z","timestamp":1685926730000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +\/- RRx-001 in newly diagnosed glioblastoma"],"prefix":"10.3389","volume":"13","author":[{"given":"Howard","family":"Fine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Caroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Oronsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nacer","family":"Abrouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Butowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"B1","volume-title":"Cancer facts & figures 2009","year":"2009"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","article-title":"Rockets, radiosensitizers, and RRx-001: an origin story part I","volume":"21","author":"Oronsky","year":"2016","journal-title":"Discov Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1268600","article-title":"RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials","volume":"26","author":"Oronsky","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.96","article-title":"A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells","volume":"30","author":"Das","year":"2016","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4155\/bio.13.331","article-title":"Development of methods for the bioanalysis of RRx-001 and metabolites","volume":"6","author":"Scicinski","year":"2014","journal-title":"Bioanalysis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/2324709618760080","article-title":"A recurrent platinum refractory ovarian cancer patient with a partial response after RRx-001 resensitization to platinum doublet","volume":"6","author":"Cottrill","year":"2018","journal-title":"J Investig Med High Impact Case Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.010","article-title":"A complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets","volume":"73","author":"Brzezniak","year":"2018","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13148-016-0220-7","article-title":"RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors","volume":"8","author":"Oronsky","year":"2016","journal-title":"Clin Epigenetics"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1002\/alz.061516","article-title":"The direct NLRP3 inhibitor and Phase 3 small molecule anticancer agent, RRx-001, protects aged triple transgenic Alzheimer\u2019s disease model mice from CNS degeneration and cognitive decline","volume-title":"Alzheimer's Dement","author":"Reid","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00683-y","article-title":"RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor","volume":"18","author":"Chen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B12","article-title":"RRx-001 is effective in temozolomide-sensitive and resistant GBM","volume-title":"Cancer Research","author":"Steri","year":"2016"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1158\/1538-7445.AM2016-2165","article-title":"Abstract 2165: Enhanced uptake and accumulation of temozolomide and irinotecan in orthotopically-implanted gliomas by vascular priming with RRx-001","volume":"76","author":"Cabrales","year":"","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4480","article-title":"NLRP3 in human glioma is correlated with increased WHO grade, and regulates cellular proliferation, apoptosis and metastasis via epithelial-mesenchymal transition and the PTEN\/AKT signaling pathway","volume":"53","author":"Yin","year":"2018","journal-title":"Int J Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40265-023-01838-z","article-title":"A review of RRx-001: a late-stage multi-indication inhibitor of NLRP3 activation and chronic inflammation","volume":"83","author":"Jayabalan","year":"2023","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.7511","article-title":"Response assessment in neuro-oncology clinical trials","volume":"35","author":"Wen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","unstructured":""},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.12.031","article-title":"PREVLAR: phase 2a randomized trial to assess the safety and efficacy of RRx-001 in the attenuation of oral mucositis in patients receiving head and neck chemoradiotherapy","volume":"14","author":"Bonomi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-017-2416-4","article-title":"RRx-001 protects against cisplatin-induced toxicities","volume":"143","author":"Oronsky","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.676396","article-title":"RRx-001 radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice","volume":"12","author":"Jurgensen","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1176448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:58:53Z","timestamp":1685926733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1176448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":20,"alternative-id":["10.3389\/fonc.2023.1176448"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1176448","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"article-number":"1176448"}}